We would love to hear your thoughts about our site and services, please take our survey here.
I should clarify, see bottom of page 12.
Https://thamesvalleycanceralliance.nhs.uk/wp-content/uploads/2024/02/Trials-Aria-February-2024.pdf
Richard Scolyer: Melanoma doctor's high-stakes gamble to treat his brain cancer
https://www.bbc.co.uk/news/world-australia-67870595
"....A clever move by Scancell ...making positions public without breaching confidence. It also injects some sense of urgency...wait too long to make your move and you miss out ! It proves the point that as time ticks on, Scancell platforms will be more expensive to buy / license."
Hi violindog, I made this exact point the other day, but you've worded it far better, I wasn't sure if the five competitors were aware of each other, seemed unlikely, so like you say it's a potentially very clever move by Scancell, and without breaking any agreements/disclosures. It should cause some panic you'd think.
And as mentioned by others, the best way to ensure exclusivity is the buy the whole lot.
Chop chop big pharma...you don't want your competitors to beat to you Scancells wares.
"31/1/2024
11:24 chilltime: Just of note on some opinions.
Further deals and timelines.
We knew they had interest but now know it’s 5.
I took the business management appointment that side last year, to indicate a need for someone with the right experience to manage and negotiate deals.
Now it’s obvious as to why they were appointed.
Some posters hope for a deal as late has Q3.
I personally think that’s a tad pessimistic and won’t be surprised to see one at least, within a month or two."
The optimist in me agrees with this. Especially as now we now there is competition amongst them.
Share prophets Nigel Somerville...
Lol.
Nothing more to say than that.
"So Seth thinks he can get £6m ish per mab on a non exclusive basis. Someone will have to go much higher for exclusivity but beware the tail which comes alongside. Many firms may notwant to play for the other assets if x is attached."
How much higher are we thinking for exclusivity? Educated guesses?
Strong finish and unusual for sclp following a presentation, no matter how good it is! Perhaps things are changing!?
P.s. Good posts today c11, but that was a bit of a unnecessary dig in your last post IMO.
An observation from the comments only as wasn't able to watch, but seemed to me like this presentation was, for the first time perhaps (?), focused more on the potential for deals/negotiations rather than the science?
If so, I'm super pleased and excited. It shows the progress and where Scancell are (finally) at now.
Another question, would the five competing parties have been aware that they were in competition with other parties until today? Was LD trying to cause some panic between them I wonder?
Yes, a running commentary would be useful please :)
Https://www.proactiveinvestors.co.uk/companies/news/1039647/scancell-geared-up-for-busy-2024-1039647.html#
https://www.proactiveinvestors.co.uk/companies/news/1039647/scancell-geared-up-for-busy-2024-1039647.html#
"30/1/2024
07:29 sci102: RNS out but no additional update on SCOPE. They should have data on at least 4-5 additional patients and hopefully they'll say more at the presentation."
Do we think there could be another intra day RNS? They seem to like those now.
"This represents a potential $1.5 billion per annum market and we anticipate significant interest from potential partners"
This is the kind of thing I want to see in an RNS. Stating the obvious perhaps but still important to say it IMO. A big clue you could say.
The more pertinent question is who is waiting in the wings.
Yes, good point Bobbust, I was just about to say the same after checking myself. Seems like the data on LSE isn't the most accurate.
Flutter not flatter*!
Thanks for highlighting bobbust, I would not have noticed that this is the first time with the half year results that there has been presentation with a q&a after.
It is interesting/intriguing. And yes perhaps "worth a flatter" indeed! But that spread isn't helping perhaps? "still" 10%, which I think is unusual in it's own right?
Https://www.spectator.co.uk/article/where-are-the-smart-investments-under-a-starmer-government/
"Where are the smart investments under a Starmer government?
3 hours ago — ... Scancell in immunology; Destiny Pharma in infection prevention; and Angle in liquid biopsy technology. Shield Therapeutics, with an iron deficiency drug."
Can't see the full article unfortunately, but get the gist. P.s. Not to start a heated debate re politics/election.
We agree to disagree on the point of the RNS titles, which is fair enough, it's the whole point of forum like this I guess.
But my point is the private investors, in particular those interested in the bio, may have had a closer look at the RNS(s) with more descriptive titles, and perhaps even smaller fund manager types, share tipsters etc. Who knows. Lots of other companies release RNS's with far more descriptive titles.
But the more interest the better IMO for the interim at least, whilst we wait for the those who will make the biggest difference i.e. big pharma.
...Plus "Exceptional results" - quite eye opening and fantastic to to see this written. Again that should have been in the RNS title and/or subtitle.
Some other observations, typical of Scancell to release another fantastic RNS on an overall terrible day for the broader market!
Also, why didn't they use the subtitle of the RNs as the actual title i.e. "MHRA approval to add a third cohort using iSCIB1+ to the SCOPE trial"
IMO having MRHA approval would certainly have piqued more interest.
Also I hadn't topped up for a while, yesterdays RNS has (re) cemented why most of us are here, so figured time for a small top up.